https://n.neurology.org/content/92/15_Supplement/S4.008
April 09, 2019; 92 (15 Supplement) MAY 5, 2019
Efficacy Result from a Phase 2, Double-Blind, Placebo-Controlled Study of CX-8998 a State-Dependent T-Type Calcium (Cav3) Channel Modulator in Essential Tremor Patients (T-CALM) (S4.008)
Spyros Papapetropoulos, Margaret Lee, Stacey Boyer, Andrew Krouse, Rajesh Pahwa, Kelly Lyons, William Ondo, H. Jinnah, Rodger Elble
First published April 16, 2019,